APLS Apellis Pharmaceuticals Inc
Price (delayed)
$24.76
Market cap
$3.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.6
Enterprise value
$3.16B
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims
Highlights
APLS's revenue has soared by 97% year-on-year and by 9% since the previous quarter
The gross profit has soared by 96% YoY and by 7% QoQ
The equity has increased by 17% year-on-year but it has declined by 3.6% since the previous quarter
Key stats
What are the main financial stats of APLS
Market
Valuations
Earnings
Shares outstanding
125.52M
Market cap
$3.11B
Enterprise value
$3.16B
Price to earnings (P/E)
N/A
Price to book (P/B)
13.48
Price to sales (P/S)
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.05
Revenue
$781.37M
Gross profit
$663.64M
Operating income
-$164.98M
Net income
-$197.88M
EBIT
-$156.33M
EBITDA
-$154.53M
Free cash flow
-$88.27M
Per share
Balance sheet
Liquidity
EPS
-$1.6
EPS diluted
-$1.6
Free cash flow per share
-$0.71
Book value per share
$1.84
Revenue per share
$6.31
TBVPS
$7.14
Total assets
$885.05M
Total liabilities
$656.51M
Debt
$469.78M
Equity
$228.54M
Working capital
$603.45M
Debt to equity
2.06
Current ratio
4.25
Quick ratio
3.65
Net debt/EBITDA
-0.37
Margins
Efficiency
Dividend
EBITDA margin
-19.8%
Gross margin
84.9%
Net margin
-25.3%
Operating margin
-21.1%
Return on assets
-22.5%
Return on equity
-79.4%
Return on invested capital
-22.4%
Return on capital employed
-22.3%
Return on sales
-20%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
APLS stock price
How has the Apellis Pharmaceuticals stock price performed over time
Intraday
-1.67%
1 week
-2.21%
1 month
-9.83%
1 year
-56.83%
YTD
-22.41%
QTD
-22.41%
Financial performance
How have Apellis Pharmaceuticals's revenue and profit performed over time
Revenue
$781.37M
Gross profit
$663.64M
Operating income
-$164.98M
Net income
-$197.88M
Gross margin
84.9%
Net margin
-25.3%
APLS's revenue has soared by 97% year-on-year and by 9% since the previous quarter
The gross profit has soared by 96% YoY and by 7% QoQ
APLS's operating margin has surged by 84% year-on-year and by 32% since the previous quarter
The company's net margin has surged by 81% YoY and by 28% QoQ
Growth
What is Apellis Pharmaceuticals's growth rate over time
Valuation
What is Apellis Pharmaceuticals stock price valuation
P/E
N/A
P/B
13.48
P/S
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.05
The EPS has surged by 64% year-on-year and by 21% since the previous quarter
The P/B is 40% less than the 5-year quarterly average of 22.9 and 28% less than the last 4 quarters average of 19.1
The equity has increased by 17% year-on-year but it has declined by 3.6% since the previous quarter
The stock's price to sales (P/S) is 98% less than its 5-year quarterly average of 227.8 and 49% less than its last 4 quarters average of 7.9
APLS's revenue has soared by 97% year-on-year and by 9% since the previous quarter
Efficiency
How efficient is Apellis Pharmaceuticals business performance
The company's return on invested capital has surged by 89% YoY and by 38% QoQ
The return on sales has surged by 84% year-on-year and by 32% since the previous quarter
APLS's ROA has soared by 63% year-on-year and by 23% since the previous quarter
APLS's ROE has soared by 56% YoY and by 24% QoQ
Dividends
What is APLS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for APLS.
Financial health
How did Apellis Pharmaceuticals financials performed over time
Apellis Pharmaceuticals's total assets is 35% more than its total liabilities
The company's quick ratio has surged by 62% YoY and by 3.1% QoQ
The company's current ratio rose by 37% YoY but it fell by 2.5% QoQ
The company's debt is 106% higher than its equity
The equity has increased by 17% year-on-year but it has declined by 3.6% since the previous quarter
The debt to equity has increased by 4% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.